ArticleJACC. Case reports2026
Eisenmenger Syndrome Complicated by Hemorrhagic Hereditary Telangiectasia: Unique Intersection of Hemorrhage, Cyanosis, and Thrombosis.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEisenmenger syndrome is an intracardiac, right-to-left shunt reversal due to a congenital defect. It can rarely co-occur alongside other noncardiac congenital abnormalities. CASE SUMMARY: A patient with known Eisenmenger syndrome secondary to a large unrepaired ventricular septal defect with concurrent genetically confirmed hereditary hemorrhagic telangiectasia (HHT) presented with acute gastrointestinal bleed. Multiple subspecialists managed the patient's unique medical challenges of ongoing hemorrhage, cyanosis, and risk for thrombosis. Diagnostic work-up included imaging to visualize arteriovenous malformations and right heart catheterization. Medical management included administration of bevacizumab, macitentan, sildenafil, midodrine, pantoprazole, and iron. DISCUSSION: This case highlights the unique hematologic pathophysiology and hemodynamic challenges of both Eisenmenger syndrome and HHT. TAKE-HOME MESSAGES: Patients with Eisenmenger syndrome and HHT are at risk for both cyanosis and bleeding-albeit by different pathophysiological mechanisms. These factors lead to complex, overlapping scenarios that can worsen both conditions in a patient dually afflicted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.